keyword
MENU ▼
Read by QxMD icon Read
search

Telbivudine

keyword
https://www.readbyqxmd.com/read/28192212/anti-hbv-drugs-suppress-the-growth-of-hbv-related-hepatoma-cells-via-down-regulation-of-hepatitis-b-virus-x-protein
#1
Shuqin Zhang, Shan Gao, Man Zhao, Yunxia Liu, Yanan Bu, Qiulei Jiang, Qiang Zhao, Lihong Ye, Xiaodong Zhang
Chronic infection of hepatitis B virus (HBV) is closely associated with the development of hepatocellular carcinoma (HCC). Meta-analyses show that adjuvant anti-HBV therapy is effective for HBV-related HCC patients in clinical. However, the significance that anti-HBV drugs depress HCC is poorly understood. Here, we investigated the effects of telbivudine (LdT), entecavir (ETV) and interferon-α2b (IFN-α2b) on HBV-related HCC. Our data showed that the treatment with the drugs significantly suppressed the growth of HBV-expressing hepatoma cells in vitro and in vivo, but failed to work in HBV-free liver cells...
February 9, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28137301/comparison-of-telbivudine-and-entecavir-on-the-change-of-off-treatment-egfr-after-3%C3%A2-years-of-treatment-in-non-cirrhotic-chronic-hepatitis-b-patients
#2
COMPARATIVE STUDY
Yang-Sheng Lin, Shou-Chuan Shih, Horng-Yuan Wang, Ching-Chung Lin, Chen-Wang Chang, Ming-Jen Chen
BACKGROUND: The change of estimated glomerular filtration rate (eGFR) with off-treatment nucleos(t)ide analogues (NA) in chronic hepatitis B patients (CHB) is unclear. This study is aimed to evaluate the off-treatment eGFR after 3 years of therapy with telbivudine (LdT) or entecavir (ETV) and to assess predictive factors for eGFR improvement. METHODS: From January 2009 to December 2011, we identified NA-naïve patients who were at least 20 years of age diagnosed with compensated CHB...
January 31, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28107377/hbeag-seroconversion-in-hbeag-positive-chronic-hepatitis-b-patients-receiving-long-term-nucleos-t-ide-analog-treatment-a-systematic-review-and-network-meta-analysis
#3
Tongjing Xing, Hongtao Xu, Lin Cao, Maocong Ye
BACKGROUND: HBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. METHODS: Network meta-analysis of NA treatment-induced HBeAg seroconversion after 1-2 years of treatment was performed. In addition, NA treatment-induced HBeAg seroconversion after 3-5 years of treatment was systematically evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28103819/telbivudine-versus-entecavir-in-patients-with-undetectable-hepatitis-b-virus-dna-a-randomized-trial
#4
RANDOMIZED CONTROLLED TRIAL
Jihyun An, Young-Suk Lim, Gi-Ae Kim, Seong-Bong Han, Wonhee Jeong, Danbi Lee, Ju Hyun Shim, Han Chu Lee, Yung Sang Lee
BACKGROUND: Telbivudine has been suggested to induce hepatitis B surface antigen (HBsAg) decline to the similar degree as pegylated interferon. We aimed to investigate whether telbivudine could further decrease HBsAg titer in patients who maintain undetectable serum hepatitis B virus (HBV) DNA after initial entecavir treatment. METHODS: In this open-label trial, patients who had serum HBsAg and HBV DNA levels ≥1,000 IU/mL and <60 IU/mL, respectively, following entecavir (0...
January 19, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28039902/long-term-safety-and-efficacy-of-telbivudine-in-infants-born-to-mothers-treated-during-the-second-or-third-trimesters-of-pregnancy
#5
G-R Han, H-X Jiang, C-M Wang, Y Ding, G-J Wang, X Yue, L Zhou, W Zhao
Telbivudine, an FDA pregnancy category B drug, has been found to reduce hepatitis B virus (HBV) perinatal transmission with no safety concerns in infants aged up to 1 year. This study evaluated the long-term efficacy and safety of telbivudine in 214 infants born to 210 pregnant women with chronic hepatitis B infection who were treated with telbivudine during pregnancy (weeks 20-32 of gestation). The infants were followed for up to 5 years after birth. The efficacy endpoint was the rate of perinatal transmission, which was established by HBsAg and HBV DNA levels at 7 and 12 months...
December 31, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28004999/a-follow-up-study-on-the-renal-protective-efficacy-of-telbivudine-for-hepatitis-b-virus-infected-taiwanese-patients-after-living-donor-liver-transplant
#6
Kuo-Hua Lin, Yao-Li Chen, Ping-Yi Lin, Chia-En Hsieh, Chih-Jan Ko, Chia-Cheng Lin, Ying-Zi Ming
OBJECTIVES: Preservation of renal function is an important issue after living donor liver transplant. We aimed to examine the renal protective efficacy of telbivudine in hepatitis B virus-infected patients after living donor liver transplant. MATERIALS AND METHODS: In this retrospective study, we compared 18 patients who received telbivudine 600 mg once per day and 23 patients who received entecavir 1 mg once per day after living donor liver transplant. Clinical data were obtained through chart review and included Model for End-Stage Liver Disease score and pre- and postoperative aspartate aminotransferase, alanine aminotransferase, and creatinine levels and estimated glomerular filtration rate...
February 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/27928739/cost-effectiveness-comparison-between-the-response-guided-therapies-and-monotherapies-of-nucleos-t-ide-analogues-for-chronic-hepatitis-b-patients-in-china
#7
Keng Lai, Chi Zhang, Weixia Ke, Yanhui Gao, Shudong Zhou, Li Liu, Yi Yang
BACKGROUND AND OBJECTIVE: Nucleos(t)ide analogue (NA) monotherapies are typically used as the primary treatment for chronic hepatitis B (CHB) patients, including lamivudine (LAM), telbivudine (TBV), adefovir (ADV), entecavir (ETV) and tenofovir (TDF). For high-resistance NAs (LAM, TBV, ADV), they can generate excellent clinical outcomes by using response-guided therapy; however, their pharmacoeconomic profiles remain unclear in China. We aimed to evaluate the cost effectiveness between response-guided therapies and monotherapies of NAs for Chinese hepatitis B e-antigen (HBeAg)-positive and -negative CHB patients...
December 7, 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27922198/dnmt1-modulation-in-chronic-hepatitis-b-patients-and-hypothetic-influence-on-mitochondrial-dna-methylation-status-during-long-term-nucleo-t-side-analogues-therapy
#8
Giordano Madeddu, Silvia Ortu, Giovanni Garrucciu, Ivana Maida, Michela Melis, Alberto Augusto Muredda, Maria Stella Mura, Sergio Babudieri
Inhibition of viral replication is the most important goal in patients with Hepatitis B virus chronic infection (CHB). Currently, five oral nucleo(t)side analogues (NAs), including Lamivudine, Adefovir, Telbivudine, Entecavir and Tenofovir, have been approved for treatment. The widespread use of NAs has also been linked with a progressive growth of unlikely anomaly attributable to mitochondrial dysfunctions, not previously recognized. Here we explore the hypothesis that NAs may cause persistent epigenetic changes during prolonged NAs therapy in CHB patients...
December 6, 2016: Journal of Medical Virology
https://www.readbyqxmd.com/read/27917266/telbivudine-vs-tenofovir-in-hepatitis-b-e-antigen-negative-chronic-hepatitis-b-patients-optima-roadmap-study
#9
Zahari Krastev, Diana Petrova, Iskren Kotzev, Mustafa Kemal Celen, Meryl Mendelson, Richa Chandra, Priti Pandey, Kamal Hamed
AIM: To make efficacy and safety comparison of telbivudine-raodmap and tenofovir-roadmap in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. METHODS: This was the first prospective, randomised, two-arm, open-label, non-inferiority study in HBeAg-negative CHB patients that compared telbivudine and tenofovir administered as per roadmap concept. Patients were treated up to 24 wk and, depending on virologic response, continued the same therapy or received add-on therapy up to 104 wk...
November 18, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27866195/comparison-of-telbivudine-and-entecavir-therapy-on-nephritic-function-and-drug-resistance-in-patients-with-hepatitis-b-virus-related-compensated-cirrhosis
#10
RANDOMIZED CONTROLLED TRIAL
Huajiang Shen, Feng Ding, Zhiwei Wang, Fang Sun, Yafeng Yu, Jiankang Zhou, Wenfang Xu, Jianchao Ni, Jiangang Wang, Yida Yang
BACKGROUND: To compare the impact of telbivudine (LDT) and entecavir (ETV) administration on nephritic function. METHOD: One hundred thirty patients diagnosed with hepatitis B virus (HBV)-related compensated cirrhosis were randomly divided into LDT (600 mg/d) or ETV (0.5 mg/d) groups. RESULTS: The drug resistance rate was higher following LDT treatment compared to ETV treatment (16.9% vs. 1.5%, P=0.0006). The mean creatinine level decreased compared to baseline in the LDT group (0...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27806120/comparison-of-the-efficacies-and-safety-of-combined-therapy-between-telbivudine-plus-adefovir-and-lamivudine-plus-adefovir-in-patients-with-hepatitis-b-virus-infection-in-real-world-practice
#11
Ming-Tsung Lin, Yi-Hao Yen, Ming-Chao Tsai, Po-Lin Tseng, Kuo-Chin Chang, Cheng-Kun Wu, Tsung-Hui Hu
BACKGROUND AND AIM: Chronic hepatitis B infection remains a significant health issue worldwide. This study evaluated the efficacy and safety of combined therapy using lamivudine plus adefovir (LAM+ADV) versus telbivudine plus adefovir (LdT+ADV) and the corresponding renal function change and safety. METHODS: This study enrolled a total of 171 patients (110 patients received LAM+ADV and 60 patients received LdT+ADV). We analyzed the changes in renal function using the estimated glomerular filtration rate (eGFR)...
2016: PloS One
https://www.readbyqxmd.com/read/27777855/telbivudine-for-the-treatment-of-chronic-hepatitis-b-in-hbeag-positive-patients-in-china-a-health-economic-analysis
#12
S Banerjee, P Gunda, R F Drake, K Hamed
BACKGROUND: Nucleos(t)ide analogs (NUCs) are the standard of care for chronic hepatitis B (CHB). The present analysis aimed to determine the cost effectiveness of NUCs in Chinese healthcare settings. METHODS: A Markov model was used to simulate two therapeutic strategies for a hypothetical patient cohort diagnosed with hepatitis B e antigen-positive CHB, unwilling or unable to receive interferon therapy, and about to start treatment with any NUC. The first strategy included NUC monotherapy without sequencing (telbivudine [LDT], entecavir [ETV], tenofovir [TDF], lamivudine [LAM], adefovir dipivoxil [ADV], and combination therapies of either LDT and ADV or LDT and TDF, followed by best supportive care [BSC])...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27761438/treatment-for-hepatitis-b-in-patients-with-drug-resistance
#13
REVIEW
Frank Tacke, Daniela C Kroy
Persistent hepatitis B virus (HBV) infections affect about 240 million patients worldwide that are at risk of developing liver cirrhosis or hepatocellular carcinoma. HBV is a small, partially double stranded DNA virus with four overlapping genes and a unique life cycle, which involves the generation of an RNA template for replication via reverse transcription. Mutations occur frequently during chronic infection, and particular selection pressures select distinct mutants. Nucleoside and nucleotide analogues like lamivudine (LMV), entecavir (ETV), telbivudine (LdT), adefovir dipivoxil (ADV) and tenofovir (TDF) are used to achieve long-term suppression of viral replication...
September 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27749537/telbivudine-treatment-of-hepatitis-b-virus-infected-pregnant-women-at-different-gestational-stages-for-the-prevention-of-mother-to-child-transmission-outcomes-of-telbivudine-treatment-during-pregnancy
#14
Zhangmin Tan, Yuzhu Yin, Jin Zhou, Lingling Wu, Chengfang Xu, Hongying Hou
This prospective study evaluated the viability of telbivudine for blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) infection.Pregnant women positive for the hepatitis B surface antigen began telbivudine treatment before 14 weeks of gestation (i.e., early), between 14 and 28 weeks of gestation (late), or not at all (control). In the late-treatment group, 55 women terminated telbivudine therapy within puerperium. All neonates underwent routine hepatitis B immunoglobulin plus vaccination...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27742868/comparative-renal-safety-assessment-of-the-hepatitis-b-drugs-adefovir-tenofovir-telbivudine-and-entecavir-in-rats
#15
Marianne Uteng, Andreas Mahl, Nicolau Beckmann, Alessandro Piaia, David Ledieu, Valerie Dubost, Elaine Tritto, Armin Wolf, Pierre Moulin, Li Li, Salah-Dine Chibout, Francois Pognan
The aim of this study was to determine the relative safety of 4 antiviral drugs (telbivudine, tenofovir, adefovir, and entecavir) against hepatitis B virus with respect to kidney function and toxicity in male Sprague Dawley rats. The antiviral drugs were administered once daily for 4 weeks by oral gavage at ∼10 and 25-40 times the human equivalent dose. Main assessments included markers of renal toxicity in urine, magnetic resonance imaging (MRI) of kidney function, histopathology, and electron microscopic examination...
October 13, 2016: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://www.readbyqxmd.com/read/27720344/long-term-outcomes-of-hepatitis-b-virus-related-cirrhosis-treated-with-nucleos-t-ide-analogs
#16
Ming-Chao Tsai, Chien-Hung Chen, Tsung-Hui Hu, Sheng-Nan Lu, Chuan-Mo Lee, Jing-Houng Wang, Chao-Hung Hung
BACKGROUND/PURPOSE: This study aimed to evaluate the outcomes of chronic hepatitis B patients with cirrhosis who received long-term nucleos(t)ide analog therapy. METHODS: A total of 546 consecutive cirrhotic patients treated with entecavir (n = 359), telbivudine (n = 104), or tenofovir (n = 83) for chronic hepatitis B were enrolled. The incidence of hepatocellular carcinoma (HCC) and overall survival were evaluated. RESULTS: During a median follow-up of 39 months, 56 (10...
October 5, 2016: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/27694733/monitoring-of-genotypic-resistance-profile-in-chronic-hepatitis-b-patients-receiving-nucleos-t-ide-analogues-in-huzhou-china
#17
Fuchu Qian, Jiqu Qin, Dongli Li, Zhihong Ma, Hairong Zhang, Fang Jin, Weihong Wang
INTRODUCTION: Antiviral drug-resistance patterns of hepatitis B virus (HBV) mutants are complex and currently partly understood. The aim of this study was to monitor the genotypic resistance profile in patients with chronic hepatitis B (CHB) receiving nucleos(t)ide analogues (NAs) in Huzhou, eastern China. METHODOLOGY: Serum samples of 139 CHB patients undergoing NA treatment were obtained from Huzhou Central Hospital. The full-length HBV reverse transcriptase regions were amplified and sequenced...
September 30, 2016: Journal of Infection in Developing Countries
https://www.readbyqxmd.com/read/27611456/clinicopathological-features-of-telbivudine-associated-myopathy
#18
Tomica Ambang, Joo-San Tan, Sheila Ong, Kum-Thong Wong, Khean-Jin Goh
Telbivudine, a thymidine nucleoside analog, is a common therapeutic option for chronic hepatitis B infection. While raised serum creatine kinase is common, myopathy associated with telbivudine is rare. Reports on its myopathological features are few and immunohistochemical analyses of inflammatory cell infiltrates have not been previously described. We describe the clinical, myopathological and immunohistochemical features of four patients who developed myopathy after telbivudine therapy for chronic hepatitis B infection...
2016: PloS One
https://www.readbyqxmd.com/read/27583985/small-surface-antigen-variants-of-hbv-associated-with-responses-to-telbivudine-treatment-in-chronic-hepatitis-b-patients
#19
Hui Dong, Bin Zhou, Hui Kang, Weirong Jin, Yongqiang Zhu, Yan Shen, Jian Sun, Shengyue Wang, Guoping Zhao, Jinlin Hou, Yungang He
BACKGROUND: Nucleos(t)ide analogues are widely used to treat chronic hepatitis B virus infection, but drug resistance is common. The role of hepatitis B virus surface gene variants in drug resistance to nucleos(t)ide analogues is unknown. We are trying to investigate the dynamics of S gene mutations and how they relate to a patient's virologic response in this study. METHODS: Thirty patients with chronic hepatitis B were enrolled and serum samples were collected at multiple time-points during treatment with telbivudine (LdT)...
September 1, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27581951/hbv-4dr-9g-test-and-its-comparison-with-inno-lipa-hbv-multi-dr-test-for-the-detection-of-drug-resistant-hepatitis-b-virus
#20
Wasun Chantratita, Keum-Soo Song, Viroj Pongthanapisith, Nipa Thongbaiphet, Kanokwan Angkanavin, Satish Balasaheb Nimse, Mukesh Digambar Sonawane, Taisun Kim
A significant proportion of patients with chronic Hepatitis B infection require antiviral therapy during their life time. The Antiviral therapy with lamivudine or adefovir or telbivudine has shown to be a major risk factor for selection of resistance. Eighty percent of patients showed a development of lamivudine-resistant strains after five years of treatment with lamivudine alone. Adefovir and telbivudine inhibit HBV with very high efficacy and have moderate incidences of drug resistance. Entecavir and tenofovir have been shown to have a higher barrier to resistance with rates of less than 1...
November 2016: Journal of Virological Methods
keyword
keyword
2108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"